.png "Insmed (NASDAQ: INSM)")
Today it was reported that the COB, Pres & CEO of Insmed (INSM), William Lewis, exercised options to sell 400,000 INSM shares at $3.40 a share, for a total transaction value of $10.4M.
Following William Lewis’ last INSM Sell transaction on November 02, 2018, the stock climbed by 9.7%. In addition to William Lewis, 2 other INSM executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Insmed’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $21.9 million and GAAP net loss of $74.15 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $68.52 million. Currently, Insmed has an average volume of 634.9K. The Company has a Price to Book ratio of 14.0241.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $45.25, reflecting a 76.8% upside.
In the last 30 days, insiders have sold $10.68M worth of INSM shares and purchased $83.52K worth of INSM shares. The insider sentiment on Insmed has been neutral according to 28 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
